Tranexamic%252525252520acid

# Tranexamic Acid ## Overview Tranexamic acid (TXA) is a synthetic lysine analog that acts as an antifibrinolytic agent by competitively inhibiting the activation of plasminogen to plasmin, thereby preventing fibrin degradation. ## Primary Indications * Treatment/prevention of hemorrhage due to primary fibrinolysis (e.g., trauma, surgical procedures). * Heavy menstrual bleeding. * Hereditary angioedema (prophylaxis). * Epistaxis or ocular hemorrhage (topical/adjunctive). ## Adult Dosing * **Trauma (CRASH-2 protocol):** 1 g IV bolus over 10 minutes, followed by 1 g IV infusion over 8 hours. Administer as soon as possible, ideally within 3 hours of injury. * **Heavy Menstrual Bleeding:** 1300 mg PO TID for up to 5 days during menses. * **Surgical Hemorrhage:** Dosing varies widely by procedure (typically 10–20 mg/kg IV bolus). Refer to institution-specific protocols. ## Pediatric Dosing * **Trauma/Systemic Hemorrhage:** 10–15 mg/kg IV bolus (max 1 g), followed by 2–10 mg/kg/hr infusion (off-label). * **Hereditary Angioedema:** 10 mg/kg PO TID (max 1.5 g/dose). * *Note: Pediatric dosing is frequently protocol-dependent; consult institutional guidelines.* ## Dose Adjustments * **Renal Impairment:** Requires dose reduction or longer dosing intervals. * CrCl 30–50 mL/min: 50% of normal dose. * CrCl 10–29 mL/min: 25% of normal dose. * CrCl < 10 mL/min: 10% of normal dose. * **Hepatic Impairment:** No specific dosage adjustment usually required, but use with caution. ## Contraindications * Hypersensitivity to the drug. * Active intravascular clotting (thromboembolic disease). * History of intracranial bleeding. * Acquired color vision disturbances (prevents monitoring of retinal toxicity). * Subarachnoid hemorrhage (concurrent risk of cerebral vasospasm). ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain, headache, back pain. * **Serious:** Thromboembolic events (DVT, PE, MI, stroke), seizures (especially with rapid IV injection or high doses), visual disturbances (retinal issues), allergic reactions (anaphylaxis). ## Key Drug Interactions * **Thrombolytics/Fibrinolytics:** Antagonistic effect; avoid concurrent use. * **Estrogens/Hormonal Contraceptives:** Potential increased risk of thrombosis. * **Factor IX complex/Prothrombin Complex Concentrates:** Theoretical increased risk of thrombosis. ## Monitoring * **Clinical:** Monitor for signs of persistent bleeding or new thromboembolic events (DVT/PE). * **Ophthalmologic:** Consider baseline and periodic eye exams if used long-term for hereditary angioedema. * **Renal:** Monitor CrCl in patients with renal impairment. ## Clinical Pearls * **Avoid Rapid IV Push:** Rapid administration can cause hypotension and seizures. Infuse slowly. * **Timing:** Efficacy in trauma is highly time-dependent; clinical benefit decreases significantly after 3 hours post-injury. * **Off-label Uses:** Commonly used off-label topically in orthopedic or plastic surgeries to reduce localized bleeding; check local protocols for concentrations. *** **Educational Disclaimer:** This information is for educational purposes only. Always verify current prescribing information, institutional protocols, and patient-specific factors via reliable clinical resources (e.g., Lexicomp, UpToDate, or official manufacturer package inserts) before prescribing or administering medication.